StemRIM

Tokyo Stock Exchange 4599.T

StemRIM Return on Assets (ROA) for the year ending July 31, 2024: -22.27%

StemRIM Return on Assets (ROA) is -22.27% for the year ending July 31, 2024, a -1,516.15% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

StemRIM Return on Assets (ROA) for the year ending July 31, 2023 was 1.57%, a 107.75% change year over year.
StemRIM Return on Assets (ROA) for the year ending July 31, 2022 was -20.30%, a -280.23% change year over year.
StemRIM Return on Assets (ROA) for the year ending July 31, 2021 was -5.34%, a -273.20% change year over year.
StemRIM Return on Assets (ROA) for the year ending July 31, 2020 was 3.08%, a 111.49% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

Tokyo Stock Exchange: 4599.T

StemRIM

CEO	Mr. Masatsune Okajima
IPO Date	Aug. 9, 2019
Location	Japan
Headquarters	Saito Bio-Incubator
Employees	45
Sector	Healthcare
Industries Biotechnology

Description

StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. It develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy; PJ2, a regeneration-inducing medicine novel peptides A and B; PJ3, a biologic regeneration-inducing protein; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. StemRIM was incorporated in 2006 and is based in Ibaraki, Japan.

Key trends

Past 5 years